Stem Cell Banking Market: Insights & Forecast with Potential Impact of COVID-19 (2020 to 2027) Vita 34, LifeCell, Global Cord Blood Corporation,…

Stem Cell Banking

A new market report by The Insight Partners on theStem Cell Banking Markethas been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

Key companies Included in Stem Cell Banking Market:- Cordlife, ViaCord (A Subsidiary of PerkinElmer), Cryo-Save AG, StemCyte India Therapeutics Pvt. Ltd., Cryo-Cell International, Inc., SMART CELLS PLUS, Vita 34, LifeCell, Global Cord Blood Corporation, CBR Systems, Inc.

Get Sample PDF Of Stem Cell Banking Market @https://www.theinsightpartners.com/sample/TIPBT00002082/

The Final Report Will Include the Impact of COVID 19 Analysis in This Stem Cell Banking Industry.

Scope of Stem Cell Banking Market:

The Stem Cell Banking market was valued at XX Million US$ in 2019 and is projected to reach XX Million US$ by 2027, at a CAGR of XX% during the forecast period. In this study, 2019 has been considered as the base year and 2020 to 2027 as the forecast period to estimate the market size for Stem Cell Banking.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Stem Cell Banking Market which would mention How the Covid-19 is Affecting the Stem Cell Banking Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Stem Cell Banking Players to fight Covid-19 Impact.

Stem Cell Banking Market: Regional analysis includes:

Further, in the research report, the following points are included along with an in-depth study of each point:

* Production Analysis Production is analyzed with respect to different regions, types, and applications. Here, the price analysis of various Market key players is also covered. *Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the global market. Another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions. *Supply and Consumption In continuation of sales, this section studies the supply and consumption of the Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part. *Other analyses Apart from the information, trade and distribution analysis for the Market, contact information of major manufacturers, suppliers and key consumers are also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure@https://www.theinsightpartners.com/buy/TIPBT00002082/

Important Key questions answered inStem Cell Bankingmarket report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

For More Information Kindly Contact: Call: +1-646-491-9876

Email:[emailprotected]

Read the original here:
Stem Cell Banking Market: Insights & Forecast with Potential Impact of COVID-19 (2020 to 2027) Vita 34, LifeCell, Global Cord Blood Corporation,...

Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 (2020-2025) | Growing Awareness About Benefits of Stem Cell Therapy to Boost the…

Global Stem Cell Therapy Market Report analyzes the production of goods, supply, sales and the current state of the market in detail. In addition, the report examines the market share of production and sales of products, as well as capacity, production capacity, sales trends, cost analysis and revenue generation. The Global Stem Cell Therapy Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Therapy market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status.

Get sample copy of Stem Cell Therapy Market [emailprotected] https://www.adroitmarketresearch.com/contacts/request-sample/691

Global Stem Cell Therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around global vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing need for higher productivity. In addition, increasing need for Stem Cell Therapy from APAC is anticipated to boost the growth of the global Stem Cell Therapy market as well.

This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

List of the Top Key Players of Stem Cell Therapy Market: Anterogen Co. Ltd. MEDIPOST Co. Ltd. Osiris Therapeutics Inc. Pharmicell Co. Ltd.

Read Complete Report with TOC: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Global Stem Cell Therapy market has been divided into product types, application and regions. These segments provide accurate calculations and forecasts for sales in terms of volume and value. This analysis shows a regional development status, including Stem Cell Therapy market size, volume and value, as well as price data.

Global Stem Cell Therapy Market is segmented based by Type, Application and Region.

Stem Cell Therapy Market Classification by Types:

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Stem Cell Therapy Market Size by End-user Application:

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The Stem Cell Therapy market report consists of information related to the geographical landscape evaluating the industry into various regions. Crucial data consisting of market share accumulated by every region, in association with sales of every region registered is mentioned in the report. The valuation conducted by each region in the base year as well as the growth rate over the predicted time period is mentioned in the report.

Some of the Main Geographic Regions included in this Report are: North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia) South America (Brazil, Argentina, Colombia) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

The Stem Cell Therapy market report provides a detailed analysis of the countries in the region, covering the key challenges, competitive landscape, and demographic analysis, that can help companies gain insight into the country-specific nuances. The analysts have also placed a significant emphasis on the key trends that drive consumer choice and the future opportunities that can be explored in the region than can help companies in revenue expansion. To gain competitive intelligence about leading companies in the sector in the region with information about their market share and growth rates.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us: Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us: Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA:+1 972-362-8199/+91 9665341414

Purchase this Report (Price 4400 USD for Single User License)@ https://www.adroitmarketresearch.com/researchreport/purchase/691

More:
Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 (2020-2025) | Growing Awareness About Benefits of Stem Cell Therapy to Boost the...

Brooks Koepka ahead of 3M Open in Minneapolis: Its pathetic what happened to George Floyd – Yahoo Sports

The PGA Tour is in the Minneapolis area this week for the 3M Open, which marks the first major sporting event held in the Twin Cities since George Floyds death in Minneapolis police custody in May.

Though its been nearly two months since his death, Brooks Koepka said the thought of it still gave him chills at TPC Twin Cities on Tuesday.

Obviously, it was tragic, Koepka said. Its pathetic what happened. To see somebodys life to go and then you watch it multiple, multiple times, its tough. I get chills right now just even thinking about it. What happened is uncalled for.

Video of Floyds arrest quickly went viral in May, as it showed a white Minneapolis police officer with his knee in Floyds neck for more than eight minutes while Floyd yelled out, I cant breathe. That officer, along with three others involved in the arrest, have all since been fired and arrested.

Floyds death sparked massive protests and movements across the country, and caused countless in the sports world to speak out and get involved.

Koepka is just the latest on the PGA Tour to address his death, too. Harold Varner III released a lengthy letter on social media in June, calling his death a senseless killing a murder and, to me, it was evil incarnate.

Tiger Woods followed suit shortly after, too, saying the shocking tragedy clearly crossed a line. Woods and Varner are the only two African-American golfers inside the top 200 in the Official World Golf Rankings.

Though it hasnt been easy, Koepka has seen positive things come in the wake of Floyds death and the movements that have followed.

If there is anything good, were starting to see change, and I think thats important, Koepka said. As a world, as people, we need to continue to grow. I think were at least bringing a light to it now.

Racism is a big issue, and I think were on our way now. People are becoming more vocal. Everyone is becoming more vocal and I think its very important, and its definitely showing.

Brooks Koepka plays his shot from the 12th tee during the third round of The Memorial Tournament on July 18, 2020, at Muirfield Village Golf Club in Dublin, Ohio. (Andy Lyons/Getty Images)

Koepka has struggled in recent weeks on Tour, and he revealed last week that he was still having left knee issues several months after undergoing a stem-cell treatment to repair a torn patella tendon.

Koepka fired an 8-over 80 in the final round of the Memorial Tournament at Muirfield Village in Ohio on Sunday, finishing the week at 12-over par and near the bottom of the pack among golfers who made the cut. He said that he underwent an MRI last week to check on his knee, too, but said it was no better than it was in October when he had to withdraw from The CJ Cup in South Korea after slipping on wet concrete, re-tearing his patella tendon.

The 30-year-old, however, refuses to cite his knee as the reason for his poor play and even said Sunday was the best it felt in a long time.

Its not an excuse to why Ive been playing bad, Koepka said. I can promise you that.

The four-time major championship winner is running out of time this season to make a run and secure his spot in the FedExCup Playoffs. Hes currently at No. 154 in the FedExCup standings, well outside of the top 125 who will qualify for the first playoff event.

He can make up significant ground over the last four weeks of the season both the PGA Championship, the first major of the season, and the World Golf Championships-FedEx St. Jude Invitational offer more points than usual Koepka knows he needs to make his move soon.

I just need to play good. Ive played so bad lately, Koepka said. Im just trying to find things. Every week, I feel like the results arent there but its getting better and better If I can bring the misses up, Ill be fine.

More from Yahoo Sports:

More here:
Brooks Koepka ahead of 3M Open in Minneapolis: Its pathetic what happened to George Floyd - Yahoo Sports

The Latest: At a Texas federal prison, more than 500 women test positive for virus – Press Herald

The latest on the coronavirus pandemic around the U.S. and the world.

FORT WORTH, Texas More than 500 women at a federal medical prison in Texas have tested positive for the coronavirus, in one of the largest confirmed outbreaks at a federal prison, the Bureau of Prisons said.

The number of confirmed cases at the Federal Medical Center-Carswell in Fort Worth jumped to 510 on Tuesday, just two days after the Bureau of Prisons reported that 200 women there had tested positive for COVID-19, the illness caused by the coronavirus. Only the federal prison in Seagoville, also located in the Dallas-Fort Worth area, had more infected inmates, with 1,156 cases as of Tuesday.

Were like a whole bunch of hamsters in a cage chasing our own tails, said Carswell inmate Holli Chapman.

Three weeks ago, the prison had reported only three confirmed cases of the virus among inmates. One prisoner, Andrea Circle Bear, died in April. On July 12, 69-year-old Sandra Kincaid became the second woman to die there from the virus.

FMC-Carswell holds female inmates with medical and mental health issues. It currently has 1,357 prisoners. Since April, many inmates have told the newspaper they were concerned the virus could spread through the prison.

One of the inmates who has tested positive for the virus is Reality Winner, a former government contractor who is serving a five-year prison sentence after she pleaded guilty to mailing a classified report to a news organization.

Carswells administration directed questions to the Bureau of Prisons. The agency said in a statement that it is taking precautions to stem the virus spread.

As with any type of emergency situation, we carefully assess how to best ensure the safety of staff, inmates and the public, the agency said. All of our facilities are implementing the BOPs guidance on mitigating the spread of COVID-19.

Last week, several women at Carswell told the Star-Telegram that the facility did not have enough sanitizing supplies or protective equipment. The woman also noted that cells are not immediately cleaned after someone tests positive. Inmate Sandra Shoulders said mattresses used by women who have tested positive are piled up in a TV room.

We feel basically abandoned, she said. (Officers) are saying theyre doing all this stuff for us, that theyre in here with us. But theyre not the ones in 24-hour quarantine, left in a 6-by-6 cell with three other people with 10 minute showers, 10 minutes to be on the phone or email to communicate with their families.

Jacksonvilles Republican mayor backs sheriffs concerns about virus safety during convention

MIAMI Jacksonville Mayor Lenny Curry said Tuesday that he agrees with the Duval County sheriff that the existing security plan and resources for the Republican National Convention are inadequate, and said he would not be comfortable hosting the event next month unless that changes.

Any event, anything we put on in the city of Jacksonville, I have to have my sheriff telling me it can be done, said Curry, the Republican co-chairman of the 2020 Jacksonville Host Committee, that he has the resources he needs and that it can be done in a safe and responsible way.

Speaking to reporters on a video call about the novel coronavirus, Curry said he, the Republican National Committee and the Jacksonville Sheriffs Office are continuing to plan for the Aug. 24-27 event in downtown Jacksonville. But he said those efforts must address concerns raised Monday by Republican Sheriff Mike Williams that planning for event security is past the point of no return.

The city and private host committee have been scrambling to fund and prepare for the bulk of the Republican convention festivities _ including President Donald Trumps acceptance speech _ since before the RNC announced June 11 it was moving most of the events to Florida from North Carolina. Trump wanted to move the convention to Florida to ensure he could celebrate his acceptance of the partys presidential nomination in a filled venue before thousands of supporters.

But a surge in novel coronavirus cases in Florida and throughout the country has forced the RNC to downsize its plans and bring in additional, outdoor venues in the downtown area.

The constant evolving of the venues has complicated the citys ability to create a security plan, Jacksonville Undersheriff Pat Ivey said Tuesday on the video call. And the pandemic, he said, has made it more difficult to bring in hundreds of outside law enforcement officers to help police the city.

The personnel number (needed), it is in the thousands, said Ivey, which is right on point with other jurisdictions that have had this exact event.

Read the full story here.

Next U.S. virus aid package could easily swell past $1 trillion

WASHINGTON The price tag for the next COVID-19 aid package could quickly swell above $1 trillion as White House negotiators haggle with Congress over money to reopen schools, prop up small businesses, boost virus testing and keep cash flowing to Americans while the virus crisis deepens in the U.S.

Senate Majority Leader Mitch McConnell on Tuesday promised a new round of direct payments to earners below a certain income level, similar to the $1,200 checks sent in the spring. President Trump insists on a payroll tax holiday for workers. And Democrats want billions to outfit schools and shore up local governments.

Treasury Secretary Steven Mnuchin and acting chief of staff Mark Meadows conferred privately with Republican senators before preparing to meet with House Speaker Pelosi and Senate Democratic leader Chuck Schumer. Trumps team is trying to broker a compromise between the Republican s emerging $1 trillion proposal with the Houses more sweeping $3 trillion bill.

Meadows told reporters the president wants to ensure the funding package meets the legitimate needs that are before the American people.

With the pandemic showing no signs of easing, officials acknowledge the daunting challenge of trying to contain the coronavirus and prevent further economic distress. The U.S. has rising infections and a death toll of 140,800, more than anywhere else in the world. The health crisis is worsening just as emergency aid is about to expire.

McConnell said Washington must develop a strategy to safely reopen schools and businesses until a vaccine can be found.

We need to carve out a new normal, the Republican leader said.

Read the full story here.

Marriott, worlds largest hotel chain, requiring guests to wear masks in common areas

Marriott Hotels will soon require guests to use facial coverings in its 7,300 hotels worldwide, chief executive Arne Sorenson announced Monday in a video.

The worlds biggest hotel chain has required employees to wear masks for months, but effective Monday, the rule will also apply to customers in all indoor public spaces, Sorenson explained after removing his own purple mask.

Health experts have made it clear that wearing face coverings in public spaces is one of the easiest steps that we can all take to protect one another and reduce the spread of covid-19, he said in the video.

Sorenson said the move adheres to safety guidelines for guests during the pandemic, published in the past week by the American Hotel and Lodging Association, an industry trade group. The guidelines call for social distancing and frequent hand-washing and ask travelers to try to forgo daily housekeeping and opt for contactless services whenever possible.

To help enable safe travel amid the ongoing challenges of covid-19, we need to come together as an industry and promote clear guidelines, which for the foreseeable future include the wearing of face coverings in indoor public spaces and practicing social distancing, said Mark Hoplamazian, chief executive of Hyatt Hotels, which requires guests in the United States and Canada to wear facial coverings.

Bethesda, Md.-based Marriott has made many other alterations to its business in the pandemic, including stepped-up cleaning protocols, changes to the check-in process, partitions, hand-sanitizing stations and signage with reminders about social distancing. The company is also developing cleaning technologies, it said on its website.

Antibody tests show virus rate is 10 times higher than reported, CDC says

CHICAGO Reported coronavirus cases vastly underestimate the true number of infections, U.S. government data published Tuesday suggest, echoing results from a smaller study last month.

The Centers for Disease Control and Prevention study says true COVID-19 rates were more than 10 times higher than reported cases in most U.S. regions from late March to early May. It is based on COVID-19 antibody tests performed on routine blood samples in 16,000 people in 10 U.S. regions.

The study likely detected infections in people who may have had no symptoms or only mild illness, and who never got coronavirus tests. Infection rates were from six times higher than reported cases in Connecticut to 24 times higher in Missouri.

Still, most people in the 10 regions had not been infected. The study was published online in JAMA Internal Medicine.

Read the full story here.

Trump, Congress square off over virus aid as crisis worsens

WASHINGTON President Trump acknowledged a big flareup of COVID-19 cases, but divisions between the White House and Senate Republicans and differences with Democrats posed fresh challenges for a new federal aid package with the U.S. crisis worsening and emergency relief about to expire.

Trump convened GOP leaders at the White House on Monday as Senate Majority Leader Mitch McConnell prepared to roll out his $1 trillion package in days. But the administration criticized the legislations money for more virus testing and insisted on a full payroll tax repeal that could complicate quick passage. The timeline appeared to quickly shift.

Weve made a lot of progress, Trump said, but added, Unfortunately, this is something thats very tough.

Read the rest of the story here.

In reversal, Israel to keep restaurants open

JERUSALEM An Israeli parliamentary committee has overturned a government decision and allowed restaurants to remain open despite new restrictive measures to try and quell the spread of the coronavirus.

The coronavirus oversight committee voted Tuesday to keep restaurants open as long as they maintain proper guidelines and appropriate social distancing between patrons. It marked the continuing of a dramatic back-and-forth battle after the government ordered restaurants closed just a few days earlier and then postponed implementation after public pressure.

The government announced its restrictions after Prime Minister Benjamin Netanyahu said interim steps were needed to avoid another general lockdown. Netanyahu has faced widespread criticism and protests in recent days over his governments handling of the pandemic and the economic fallout from an earlier lockdown.

But many of the measures, such as the closing down of beaches and public pools, have been scaled back in recent days amid an outcry that they were excessive.

The frequent reversals, however, have only sown frustration, confusion and more public anger.

Health Minister Yuli Edelstein condemned the parliamentary decision, saying it would endanger public health and likely lead to another lockdown.

By late May, Israel had largely contained its outbreak following a two-month lockdown. But cases have soared in the weeks since restrictions were lifted, with Israel reporting close to 2,000 new cases a day last week. At least 422 people have died since the outbreak began, out of a total of more than 52,000 cases.

Serbian doctors protest government virus team

BELGRADE, Serbia Some 350 Serbian doctors are demanding the resignation of a government-appointed team fighting the coronavirus spread, describing the health situation in the Balkan state as catastrophic.

In an open letter entitled United Against Covid, first carried by the independent N1 television on Tuesday, the doctors said it is their moral and professional obligation to demand an independent investigation into the work of the state team.

The probe would include possible cover-up in the real number of coronavirus cases and deaths that have been declared by the team and possible political influence on its decisions ahead of an election.

The letter says that a complete lifting of anti-coronaviorus measures weeks ahead of the June 21 parliamentary election, when mass gatherings without social distancing were allowed, led to the loss of control over epidemic situation in the country, leading to a large second wave of infections.

State team members have vehemently denied previous such claims.

Nepal to resume air travel

KATHMANDU, Nepal Nepals government has decided to resume both domestic and international flights next month.

Tourism Minister Yogesh Bhattarai said the government will allow flights beginning Aug. 17. It was still undecided on the types of visitors who would be allowed in the country and visitors from which countries.

Flights had been stopped in March when the country was in full lockdown to prevent the spread of the coronavirus. Only chartered and repatriation flights were allowed to fly out stranded tourists from Nepal and bring in Nepalese workers and residents.

The government eased the lockdown last month, allowing businesses to open and government offices to resume work. Schools remain closed and there are still some restrictions on public transportation. Special permission is required for the public to travel between different cities in Nepal.

The country has 17,844 cases of virus infection and 40 deaths from COVID-19.

Invalid username/password.

Please check your email to confirm and complete your registration.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.

Previous

Next

More:
The Latest: At a Texas federal prison, more than 500 women test positive for virus - Press Herald

Maui Economic Development Board kicks off their 2020 STEM Drive – Maui Time

Maui Economic Development Board (MEDB) announces the kick-off of their first-ever 2020 STEM Drive, a benefit for the MEDB Ke Alahele Education Fund. This online fundraiser runs now through August 15, 2020. Visitwww.MEDBpathways.org.

Donations received will go towards advancing MEDBs Science, Technology, Engineering and Math (STEM) programs from kindergarten to careers; as well as helping MEDB continue to support meaningful pathways that benefit the lives of our residents in Maui County and statewide. Contributions are 100 percent tax deductible.

According to Leslie Wilkins, MEDBs President and CEO, For the past 13 years, our community has gathered in August for our annual Ke Alahele Education Fund dinner and auction to raise needed funds to support STEM education in Hawaii. This year, to protect the health and safety of our community, we will not be hosting our traditional in-person gala. However, the public can still make a difference in the lives of our keiki by donating to our STEM Drive.

Since the Fund was launched in 2006, MEDBs STEM programs continue to empower students and teachers across our state. To date, 344 grants have gone to support needed STEM equipment, robotics programs, media labs, environmental/sustainability projects, internships, training for our teachers and more.

To make a donation, please visit the MEDB STEM Drive website http://www.MEDBpathways.org. Donations can be made online or my mailing a check to Maui Economic Development Board, at 1305 N. Holopono Street #1, Kihei, HI 96753. A variety of sponsorship opportunities are also available that include publicity on the events website and social media.

This website also includes information about the MEDB Ke Alahele Education Fund, inspiring stories of those who have benefited from MEDBs STEM programs, and highlights of the upcoming STEM Week in Maui County.

Jobs today and in the future depend on the preparation of our students in critical thinking, communication, problem solving, collaboration, and creativity all skills nurtured by STEM education, said Wilkins. The MEDB Ke Alahele Education Fund was created to provide STEM tools for our youth and educators in an effort to open doors to emerging career opportunities. We extend a heartfelt mahalo to all those who have supported the Ke Alahele Education Fund in the past and hope you are able to make a contribution this year. Its truly an investment in our youth one that will help to shape our community and our world.

About MEDB

The Maui Economic Development Board (MEDB) is a 501(c)(3) not-for-profit corporation established in 1982 with a focus on diversifying Mauis economy. MEDB partners with the private, public and nonprofit sectors at the local and national levels to achieve our goals. Our programs which are founded on a respect for our culture and precious environment assist growth industries, educate and train our residents for new career pathways, and build consensus in addressing our communitys challenges and opportunities.

Photo credit Maui Economic Development Board

comments

Excerpt from:
Maui Economic Development Board kicks off their 2020 STEM Drive - Maui Time

Homology Medicines Appoints Jeff Poulton to the Board of Directors – BioSpace

- Executive with Extensive Rare Disease Expertise in Global Finance andCommercial Operations -

BEDFORD, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Homology MedicinesInc. (Nasdaq: FIXX), a genetic medicines company, announced today that Jeff Poulton has been appointed to the Board of Directors. Mr. Poulton is the Chief Financial Officer at Alnylam. Mr. Poulton brings 25 years of experience to Homologys Board of Directors, including leading finance, business development and commercial operations at companies using differentiated technologies to develop treatments for patients with rare diseases.

I had the pleasure of working with Jeff before, and I know first-hand how his strategic financial and operational leadership contributed to the success of a global rare disease commercial business, said Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. Jeff has also displayed a long-term commitment to help patients and their families, which aligns with Homologys mission to develop our gene therapy and nuclease-free gene editing platform into new treatments and potential cures. He joins at an important time in the development of our pipeline, and we look forward to his guidance as we progress our Phase 1/2 pheNIX gene therapy clinical trial for adults with PKU and work toward bringing our other development candidates to the clinic.

Prior to his role at Alnylam, Mr. Poulton served as CFO at Indigo Agriculture where he supported the initial commercial scale-up of the business, including expansion outside the US. Mr. Poulton previously held various roles of increasing responsibility at Shire Plc, concluding his service as CFO and a member of its Executive Committee and Board of Directors. During his tenure at Shire, Mr. Poulton led the rare disease commercial operations in the US, Latin America, and Asia Pacific, as well as its global rare disease business unit. Prior to Shire, he led corporate finance and business development initiatives in both the energy and materials manufacturing sectors in financial leadership positions at Cinergy Corp and PPG industries. He also served in the US Navy as a Commissioned Officer. Mr. Poulton has an MBA in Finance from the Kelley School of Business at Indiana University and a bachelors degree in Economics from Duke University. He also serves as a member of the Board of Directors at EIP Pharmaceuticals.

I am drawn to companies with transformative technologies, and I believe Homologys genetic medicines platform has the potential to change the lives of patients with rare diseases, said Mr. Poulton. I look forward to working with the team at Homology, many of whom have successful careers in developing and commercializing drugs at prior companies that are continuing to make a positive impact in the lives of patients and families living with rare diseases.

About Homology Medicines, Inc. Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homologys proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicinesin vivoeither through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visitwww.homologymedicines.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our genetic medicines platform; the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; and our position as a leader in the development of genetic medicines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the capabilities and potential expansion of our manufacturing facility; risks relating to the regulatory approval process; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 and our other filings with theSECcould cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Follow this link:
Homology Medicines Appoints Jeff Poulton to the Board of Directors - BioSpace

Stem Cell Therapy and Regenerative Medicine with Dr. Mayo …

Dr. Friedlis tells the Patch about his Stem Cell Arts practice, an affiliate of National Spine and Pain Centers and its cutting edge techniques that patients overcome chronic pain with non-surgical procedures.

Patch: What is Stem Cell Therapy and Regenerative Medicine (or Platelet Therapy)?

Dr. Friedlis: Stem Cell Therapy and Platelet Therapy / platelet rich plasma (PRP) therapy are revolutionary non-invasive medical procedures that relieve pain. These treatments promote the long lasting healing of musculoskeletal conditions for common injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis, using the natural healing properties of the patient's own stem cells. Stem cells are used to heal damaged tissue, ligaments, cartilage, and bone while managing pain. The stem cells are harvested from the patient's own hip bone marrow via syringe, concentrated, and then re-injected into injured tissue in other areas of the body. These stem cells then act as a 'booster' for the body's natural healing process and enable the patient to heal without the use of foreign materials or surgery. These rapidly emerging techniques are showing exciting success with osteoarthritis of the knee, shoulder, hip, and spine, rotator cuff tears, chronic plantar fasciitis, anterior cruciate ligament (ACL) injuries, pelvic pain and instability, back and neck injuries, tennis elbow, ankle sprains, tendonitis, and ligament sprains.

Patch: What can Stem Cell Therapy and Regenerative Procedures do for a prospective patient?

Dr. Friedlis: Stem Cell Therapy and Regenerative Procedures are viable alternatives for individuals who may be considering elective surgery or joint replacement due to injury or arthritis, we offer these procedures to patients wishing to avoid lengthy periods of downtime and painful rehabilitation that come with invasive surgeries.

Patch: Am I Too Old or Too Injured to have Stem Cells Work for me?

Dr. Friedlis: Age and level of injury are not typically a factor in a regenerative procedure because the treatment is noninvasive and stimulates the body's natural healing mechanisms. The risk of surgical treatment for older patients or those with existing injuries is greatest during the recovery period. Because stem cell therapy is non-invasive, complications during the recovery are not a concern.

Typically, patients come see us for one of three reasons. The first of those being that the patient is younger, and due to either a genetic condition or injury, is facing joint replacement at an early age. Often what happens, over long periods of time, is that the replacement joint will experience wear and the patient will need another replacement surgery to remedy the problem. By seeking regenerative treatment, we are able to help our younger patient manage the pain enough to delay the need for surgery. That way the patient will only have to undergo one joint replacement surgery in their lifetime instead of two or three.

The second reason many patients come is that they cannot afford to take the required amount of downtime necessary to recover from traditional surgical treatments for musculoskeletal ailments. Because our treatment is noninvasive, patients are able to quickly recover and begin the healing process, allowing them to get back to their everyday lives.

The third type of patient that visits us are those who have already had surgical treatments to help manage their condition, however are still suffering from pain. In partnership with their orthopedic surgeons, we use regenerative therapies in adjunct to their traditional therapy to help the patient manage their pain.

Each patient has a unique situation when they visit us. Because of that, each treatment is customized to meet the individual patient's needs.

Patch: What attracted to you to this industry, and how did you start?

Dr. Friedlis: As a physician in pain management, I became frustrated with the lack of solutions to truly fix my patients. There are many excellent methods to controlling pain using traditional medicine. However, those methods are often used to simply hide the problem. Regenerative medicine enables us to help manage the root cause of the patient's pain by preserving and improving the body's function with little or no downtime. That way our patients can get back to doing the things they love sooner.

Patch: What's the biggest challenge or most difficult moment you've faced in your job?

Dr. Friedlis: I have been among the first to adopt regenerative therapies after much scientific review. The science of these newer procedures and therapies is still not at the level of a double blind study; the most rigorous and expensive research method. So, I would say that one difficulty is facing naysayers who are not open to newer methods for non-surgical treatments that harness the body's ability to heal. Luckily, patients are getting the word out. Our network has a full-time research team studying the outcomes of several thousand patients over the course of several years. The studies are demonstrating positive results, such as pain reduction across the knee, shoulder, hip, and elbow, as well as other joint, ligament, and tendon conditions.

Patch: What advice would you give a person just starting in your industry?

Dr. Friedlis: Regenerative medicine is a very specialized field that requires a significant amount of training. Because of the progressive nature of the practice, unfortunately, the skill and knowledge that you need cannot be obtained through today's standard medical training.

In order to achieve the level of expertise required, you need to be diligent in educating yourself in regenerative medicine and take it upon yourself to stay well versed in the latest advancements in the field. You need to always be scouring the web for blogs and latest findings from people all over the world on the subject matter to keep track of all the advancement that people are making.

Regenerative medicine is a work in progress. However, you have a responsibility to stay on top of the latest and best practices being used globally so you can provide and deliver top quality care to your patients.

What's the best piece of advice you've ever been given?

Dr. Friedlis: The best piece of personal advice I received was to marry my wife. However, on a more professional level, the best piece of advice I received was to always have the courage to think outside of the box when trying to find solutions for your patients. By only sticking to the traditional menu of medical solutions, we as physicians may be missing some important treatments that can make a real difference in our patients' lives. I have been fortunate to find partners in Dr.'s Wagner and Dade, who are like-minded.

Patch: How did you come up with the name of your business?

Dr. Friedlis: The name of our business, Stem Cell Arts, is a direct reflection of what we do. In our practice, Dr. Rodney Dade, Dr. Robert Wagner, and I integrate over a decade of experience in using a patient's own stem cells to manage pain with the science and art required to successfully implement some of today's most progressive medical research and techniques in a rapidly advancing field.

Patch: What's the best part about doing business in your town?

Dr. Friedlis: Living in Potomac, Maryland and working in Chevy Chase, Maryland and Tysons/McLean, Virginia allows me to meet a variety of extremely interesting, engaging, and diverse people. The most gratifying aspect of what I do is helping patients get back to the things they desire to dobe it working, exercising, travelingyou name it. I also enjoy treating multiple members of one family and getting to know them well.

Patch: If you were to get an indulgent snack in your town, where would you go and what would you get?

Dr. Friedlis: I would have to say Moby Dicks. The food is healthy, prepared fresh, and well done. Overall, I find it very satisfying.

Here is the original post:
Stem Cell Therapy and Regenerative Medicine with Dr. Mayo ...

3 Ways Predictive Analytics is Advancing the Healthcare Industry – HealthITAnalytics.com

Source: Getty Images

July 21, 2020 -As the healthcare industry has increasingly aimed to deliver proactive, quality care, predictive analytics models have emerged as viable tools for improving outcomes and cutting costs.

From mapping the spread of infectious diseases, to forecasting the potential impact of certain conditions, predictive analytics tools can help organizations stay one step ahead in an unpredictable industry.

Researchers and provider organizations are applying predictive analytics techniques to improve practices across the care continuum, leading to more informed decision-making and better patient care.

Throughout the COVID-19 pandemic, predictive analytics models have played a major role in helping healthcare leaders track and prepare for the spread of the virus.

Researchers at the University of Texas Health Science Center at Houston (UTHealth) recently developed a new COVID-19 tracking tool that leverages predictive modeling to help mitigate the impact of the virus.

READ MORE: Predictive Analytics Model Examines Droplets to Map COVID-19 Spread

We created this interactive public health dashboard because we wanted to help our fellow Texans. By understanding future trends of this virus, it can help aid in the effective management of local resources, said Jos-Miguel Yamal, PhD, an associate professor of biostatistics and data science at UTHealth School of Public Health in Houston and one of the projects lead developers.

The interactive tool is freely available to the community to inform public health decision-making across the state. In addition to the figures for the daily number of confirmed cases throughout the state, the tool provides charts that show the measure of contagiousness of each COVID-19-positive individual in the region.

The dashboard identifies the current hot spots, predicts future spread both at the state and county level, and houses relevant public health resources. It can effectively inform decision-makers across Texas to help mitigate the spread of COVID-19, said Shreela Sharma, PhD, a member of the research team and professor of epidemiology, human genetics, and environmental sciences at UTHealth School of Public Health in Houston.

A team at CommonSpirit Health has also leveraged predictive analytics tools to help public health officials better prepare for the spread of COVID-19. The organization used de-identified cell phone data, public health information, and data from its own care sites to build predictive models and gain insight into COVID-19 dips and surges.

We started looking at the first peaks of the virus, and there were enough cases for us to do some modeling and prediction. Now, just three months later, we're looking at the same virus as people are getting back together and the contact rate is going up. And we're trying to manage this resurgence in our markets, Joseph Colorafi, MD, System VP of Clinical Data Science for CommonSpirit Health, told HealthITAnalytics.

READ MORE: Predictive Analytics Model Forecasts COVID-19 Risk, Outcomes

Researchers have also applied predictive analytics techniques to manage and stem the onset of chronic conditions.

A study recently published in Diabetes Care showed that building predictive models with patient data, including history of comorbidities and medications, can determine the five- to ten-year life expectancy of older adults with diabetes and help providers develop personalized treatment plans.

The guidelines don't give doctors guidance for how to decide whether or not people fall into these different bins for life expectancy,saidKevin Griffith, research analyst at the Department of Veterans Affairs (VA) Boston Healthcare System.

Furthermore, clinicians are notoriously inaccurate in predicting life expectancy, with studies frequently showing both over- and underestimating. We developed models with high predictive validity of future mortality in a large sample of older veterans with diabetes.

The models could help providers use shared decision-making to establish A1c target ranges that balance treatment and risks. The models could also serve as comprehensive clinical decision support tools for diabetes management and care.

READ MORE: 60% of Healthcare Execs Say They Use Predictive Analytics

Predictive analytics tools can also help improve chronic disease prevention. Researchers from Mount Sinai recently developed new predictive analytics tools and identified environmental risk factors that could lead to a new understanding of what triggers Crohns disease.

Early identification of individuals at high risk for disease development could allow for close monitoring and interventions to delay, attenuate, or even halt disease initiation, said Jean-Frederic Colombel, MD, Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai and Co-Director ofMount Sinais Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center.

This is highly relevant as we seek to predict and prevent IBD, which continues to sharply increase in numbers across the globe. In the absence of a cure, our clinical strategy will center on aggressive and innovative mechanisms to predict and prevent the disease.

Using predictive analytics models, researchers and provider organizations can also prepare for potential future trends and events that impact clinical care delivery.

In a study published in the Lancet Public Health, researchers showed that a big data model projected that without any changes in alcohol consumption or interventions to address high-risk drinking, deaths from alcohol-related liver disease will rise significantly in the US.

The studys results revealed that lawmakers should consider taking measures to curb high-risk drinking across the country.

Our study underscores the need to bring alcohol-related disease to the forefront of policy discussions and identify effective policies to reduce high-risk drinking in the US,saidsenior authorJagpreet Chhatwal, a senior scientist at theMGH Institute for Technology Assessmentand an assistant professor at Harvard Medical School.

On a smaller scale, researchers can use predictive analytics tools to get ahead of adverse healthcare events in individual patients. Recent research funded by the National Institute on Minority Health and Health Disparities showed that a simple risk prediction model helped forecast stroke risk in adult patients who have migraine with aura.

The model could help providers identify patients at high risk and intervene before the stroke occurs.

People who have migraine with aura are at increased risk for anischemic stroke, said Souvik Sen, MD, MPH, study co-author, and professor and chair of the neurology department at the University of South Carolina School of Medicine in Columbia, South Carolina. With our new risk-prediction tool, we could start identifying those at higher risk, treat their risk factors and lower their risk of stroke.

Read more here:
3 Ways Predictive Analytics is Advancing the Healthcare Industry - HealthITAnalytics.com

SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45(-) Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike…

This article was originally published here

Stem Cell Rev Rep. 2020 Jul 20. doi: 10.1007/s12015-020-10010-z. Online ahead of print.

ABSTRACT

Angiotensin-converting enzyme 2 (ACE2) plays an important role as a member of the renin-angiotensin-aldosterone system (RAAS) in regulating the conversion of angiotensin II (Ang II) into angiotensin (1-7) (Ang [1-7]). But at the same time, while expressed on the surface of human cells, ACE2 is the entry receptor for SARS-CoV-2. Expression of this receptor has been described in several types of cells, including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which raises a concern that the virus may infect and damage the stem cell compartment. We demonstrate for the first time that ACE2 and the entry-facilitating transmembrane protease TMPRSS2 are expressed on very small CD133+CD34+LinCD45 cells in human umbilical cord blood (UCB), which can be specified into functional HSCs and EPCs. The existence of these cells known as very small embryonic-like stem cells (VSELs) has been confirmed by several laboratories, and some of them may correspond to putative postnatal hemangioblasts. Moreover, we demonstrate for the first time that, in human VSELs and HSCs, the interaction of the ACE2 receptor with the SARS-CoV-2 spike protein activates the Nlrp3 inflammasome, which if hyperactivated may lead to cell death by pyroptosis. Based on this finding, there is a possibility that human VSELs residing in adult tissues could be damaged by SARS-CoV-2, with remote effects on tissue/organ regeneration. We also report that ACE2 is expressed on the surface of murine bone marrow-derived VSELs and HSCs, although it is known that murine cells are not infected by SARS-CoV-2. Finally, human and murine VSELs express several RAAS genes, which sheds new light on the role of these genes in the specification of early-development stem cells. Graphical Abstract Human VSELs and HSCs express ACE2 receptor for SARS-CoV2 entry. Interaction of viral spike protein with ACE2 receptor may hyperactivate Nlrp3 inflammasome which induces cell death by pyroptosis. SARS-CoV2 may also enter cells and eliminate them by cell lysis. What is not shown since these cells express also Ang II receptor they may hyperactivate Nlrp3 inflammasome in response to Ang II which may induce pyroptosis. Our data indicates that Ang 1-7 may have a protective effect.

PMID:32691370 | DOI:10.1007/s12015-020-10010-z

Visit link:
SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45(-) Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike...

Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth, Industry Outlook: Post COVID-19 Investors Eye Bigger-Than-Expected | Orion Pharma,…

Global Amyotrophic Lateral Sclerosis Treatment Market By Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease, Wohlfart-Disease), Drug Type (Riluzole and Edaravone (Radicava)), By Distribution Channel (Hospital Pharmacies, and Retail & Online Pharmacies), Treatment type (Chemotherapy, Stem cell therapy) End- User (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends & Forecast to 2026

Get a sample copy of report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-amyotrophic-lateral-sclerosis-treatment-market

Few of the major competitors currently working in the amyotrophic lateral sclerosis treatment market are Sanofi (France), Mitsubishi Tanabe Pharma Corporation (Japan), BrainStorm Cell Limited (US), ViroMed Co., Ltd (South Korea), Ionis Pharmaceuticals (US), Genervon Biopharmaceuticals, LLC (US), Biogen (US), ORPHAZYME A/S (Denmark), Orion Pharma (Finland), Kringle Pharma, Inc. (Japan), Aquestive Therapeutics (US), Apotex Inc (Canada), Bausch Health Companies Inc. (Canada), Neuralstem, Inc. (US), Implicit Bioscience (Australia), F. Hoffmann-La Roche Ltd (Switzerland), TREEWAY (Netherlands), CYTOKINETICS, INC. (US), AB Science (France), Advanz Pharmaceutical (Canada) and few among others.

Market Analysis:Global Amyotrophic Lateral Sclerosis Treatment Market

Global amyotrophic lateral sclerosis treatment market is expected to rise gradually to an estimated value of USD 3.6 billion by 2026, registering a CAGR of 21.6% in the forecast period of 2019-2026 with the annual sales of USD 0.75 billion in the year of 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Market Definition:Global Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, also known as motor neuron disease (MND) and Lou Gehrigs disease that affects nerve cells (motor neurons) of brain, brain stem and spinal cord that controls voluntary muscles. This disease is progressive in nature.

According to Centers for Disease Control and Prevention, there were approximately 14,000 15,000 people in US in 2016 having ALS, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.

Market Drivers

Market Restraints

Make an Inquiry Before Buying @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-amyotrophic-lateral-sclerosis-treatment-market

Segmentation: Global Amyotrophic Lateral Sclerosis Treatment Market

By Disease Type

ByDrug Type

By Distribution Channel

By Treatment Type

By End- User

ByGeography

Key Developments in the Market:

Competitive Analysis:

Global amyotrophic lateral sclerosis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of amyotrophic lateral sclerosis treatment market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

Customization of the Report:

Get a discount on this research report @https://www.databridgemarketresearch.com/request-a-discount/global-amyotrophic-lateral-sclerosis-treatment-market

More:
Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth, Industry Outlook: Post COVID-19 Investors Eye Bigger-Than-Expected | Orion Pharma,...